*The S&P 500 has gained in September, but weakness across equal-weighted, small-cap, mid-cap, and most sector indexes revealed narrow leadership. *Surging Treasury yields and expectations for ...

General Mills (GIS) is modestly lower after beating EPS expectations and reaffirming its FY27 outlook in its Q1 (Aug) report this morning. Reported revenue declined 3% yr/yr to $4.4 bln, largely ...

Accenture (ACN) is nicely higher today after announcing Friday that it partnered with Anthropic to establish a team of embedded evaluators that will work alongside Anthropic's internal teams to ...

Generac (GNRC +16%) is surging higher today after announcing that it issued a warrant to Amazon (AMZN) to acquire up to 1,693,745 shares at an exercise price of $200.9266 per share. Generac said ...

*The FOMC voted 12-0 to raise the target range for the fed funds rate by 25 basis points. *Bond yields spiked in reaction to Fed Chair Warsh's comments. *The latest move by the FOMC was a "hawkish ...

Snowflake (SNOW) is up 24% after hours after a broad Q2 beat and sharply higher guidance demonstrated that AI demand is translating into faster platform consumption rather than remaining a long-term ...

MongoDB (MDB) is down sharply in pre-market action despite delivering a broad Q2 beat-and-raise, as investors focused on Atlas growth easing from approximately 29% to a guided 26% in Q3 and the ...

lululemon athletica (LULU) is under pressure after disappointing with its Q2 (Jul) results last night, with shares falling below $100 for the first time in several years. EPS of $2.92 included a $0.86 ...

*The August Consumer Price Index didn't produce enough progress on inflation. *Various market signals are pointing to a rate hike at the September 15-16 FOMC meeting. *The Fed's inflation-fighting ...

2-yr: UNCH at 4.35% 3-yr: +1 bp to 4.42% 5-yr: +1 bp to 4.52% 10-yr: +2 bps to 4.78% 30-yr: +2 bps to 5.27% ...

Eli Lilly (LLY) is edging lower despite agreeing to acquire Merida Biosciences for up to $2.875 bln in cash and reporting encouraging one-year Phase 3b data for Taltz used with Zepbound in patients ...